A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Benralizumab (Primary) ; Influenza virus vaccine
- Indications Asthma
- Focus Pharmacodynamics; Registrational
- Acronyms ALIZE
- Sponsors AstraZeneca
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History